A new study positions plant-based protein expression platforms as a viable alternative to traditional mammalian cell culture for biopharmaceutical manufacturing in the Global South. The authors contend that the complexity and high cost of current mammalian systems make them unsuitable for resource-constrained environments.
Plant expression platforms, which leverage engineered crops like tobacco or duckweed to produce therapeutic proteins, promise significantly lower capital and operating expenses. The study highlights their potential to reduce dependence on cold-chain logistics and expensive sterile facilities, enabling decentralized production of drugs ranging from vaccines to monoclonal antibodies.
The analysis did not specify which particular drugs or clinical phases were assessed, but it broadly targets the need for sustainable biomanufacturing capacity in low- and middle-income countries. This approach could address chronic shortages of biologics in regions where infrastructure for traditional bioreactors remains limited.
Proponents note that plant-based systems have already been used to produce experimental vaccines, including for COVID-19, but commercial adoption has been slow due to regulatory hurdles and yield variability. The study calls for increased investment in downstream processing tailored to plant-derived products.
Critics caution that the lower expression levels observed with some plant systems could offset cost advantages, and regulatory frameworks for these products remain less established than for mammalian cell lines. The authors acknowledge that scalability and purification efficiency require further validation before widespread deployment.